Outlook Therapeutics, Inc. OTLK

Access the segment here ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in a Virtual Investor CEO Connect segment discussing the significance of the FDA approval of LYTENAVA and the Company’s plans for its U.S.

Kevin Lundquist Kevin Lundquist Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industriesDeep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure Appointment strengthens financial and operational infrastructure as Company prepares for U.S. commercial launch following FDA approval of LY

Video webcast now available here ISELIN, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in the Virtual Investor “Why Now” on-demand conference. During the segment, Mr. Jahr highlighted why he believes Outlook Therapeuti

Outlook Therapeutics stock has been through a very rough stretch over the past few years, and the current checks suggest it still does not screen as a clear bargain despite the recent approval and upcoming launch plans for LYTENAVA. Over the last 5 years, Outlook Therapeutics has delivered a share price decline of about 98%, which shows how much long term holders have seen their investment erode. The planned U.S. commercial launch of FDA approved LYTENAVA, funded in part by a roughly US$55m...

Moby summary of Outlook Therapeutics, Inc.'s Q3 2026 earnings call

The only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA, including broad market access, reimbursement, pricing, medical affairs, and supply capabilities Potential to exceed $500 million in annual U.S. LYTENAVA sales by 2030 Company to host corporate update conference call today, August 14th, at 8:30 AM ET — registration details below ISELIN, N.J., Aug

Outlook Therapeutics is looking to sell about 55.6 million common shares, accompanied by warrants, at a 10% discount over the stock’s closing price on Wednesday.

ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying warrants to purchase up to an aggregate of 55,555,556 shares of its common stock. The combined p